Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy

• Published in: Journal for immunotherapy of cancer Vol. 9; no. 11; p. e002614
• Main Authors: Munoz, Luis Enrique, Huang, Lei, Bommireddy, Ramireddy, Sharma, Richa, Monterroza, Lenore, Guin, Rohini N., Samaranayake, Sarah G., Pack, Christopher D., Ramachandiran, Sampath, Reddy, Shaker J.C., Shanmugam, Mala, Selvaraj, Periasamy
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group Ltd 01-11-2021; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Original research
• Subjects: adjuvants; Animals; Antibodies; Antidiabetics; Antigens; B7-H1 Antigen; Cancer; Cancer Vaccines - pharmacology; Cancer Vaccines - therapeutic use; Cell death; Cytokines; Female; Humans; Hypoglycemic Agents - pharmacology; Hypoglycemic Agents - therapeutic use; immunogenicity; immunologic; Immunotherapy; Immunotherapy - methods; Kinases; Metastasis; Metformin - pharmacology; Metformin - therapeutic use; Mice; Oncolytic and Local Immunotherapy; programmed cell death 1 receptor; Proteins; Tumors; vaccination; vaccine; Vaccines; programmed cell death 1 receptor; vaccine; immunotherapy; immunologic; immunogenicity; adjuvants; vaccination
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2021-002614

BackgroundPD-L1 is one of the major immune checkpoints which limits the effectiveness of antitumor immunity. Blockade of PD-L1/PD-1 has been a major improvement in the treatment of certain cancers, however, the response rate to checkpoint blockade remains low suggesting a need for new therapies. Metformin has emerged as a potential new drug for the treatment of cancer due to its effects on PD-L1 expression, T cell responses, and the immunosuppressive environment within tumors. While the benefits of metformin in combination with checkpoint blockade have been reported in animal models, little remains known about its effect on other types of immunotherapy.MethodsVaccine immunotherapy and metformin were administered to mice inoculated with tumors to investigate the effect of metformin and TMV vaccine on tumor growth, metastasis, PD-L1 expression, immune cell infiltration, and CD8 T cell phenotype. The effect of metformin on IFN-γ induced PD-L1 expression in tumor cells was assessed by flow cytometry, western blot, and RT-qPCR.ResultsWe observed that tumors that respond to metformin and vaccine immunotherapy combination show a reduction in surface PD-L1 expression compared with tumor models that do not respond to metformin. In vitro assays showed that the effect of metformin on tumor cell PD-L1 expression was mediated in part by AMP-activated protein kinase signaling. Vaccination results in increased T cell infiltration in all tumor models, and this was not further enhanced by metformin. However, we observed an increased number of CD8 T cells expressing PD-1, Ki-67, Tim-3, and CD62L as well as increased effector cytokine production after treatment with metformin and tumor membrane vesicle vaccine.ConclusionsOur data suggest that metformin can synergize with vaccine immunotherapy to augment the antitumor response through tumor-intrinsic mechanisms and also alter the phenotype and function of CD8 T cells within the tumor, which could provide insights for its use in the clinic.